ONSPIRA THERAPEUTICS is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Our lead program is a novel, inhaled interleukin-1 alpha & beta (IL-1 𝛼 & β) receptor antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. A second program will focus on idiopathic pulmonary fibrosis.
More information regarding our pipeline and progress will be forthcoming. Check back soon for updates.